After springing to global recognition for its rapid development of a novel and highly effective coronavirus vaccine with global partner Pfizer Inc., BioNTech SE is now planning to expand its global footprint through a new Asia Pacific regional headquarters in Singapore.
The Southeast Asian city state will also be home to a planned fully integrated manufacturing facility for mRNA vaccines and therapeutics, which the German company anticipates will be operational as early as
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?